Zai Lab (09688.HK) (ZLAB.US) announced that the National Medical Security Administration has released the updated 2024 National Medical Insurance Drug Catalogue, and has included the company's 'A Keylok' (Ripotinib) in the new version of the National Medical Insurance Drug Catalogue for the treatment of ROS1-positive local advanced or metastatic non-small cell lung cancer in adult patients.
In addition, the group's 'Nuzale' (Omacetaxine) intravenous infusion and 'Qing Le' (Ripatinib) successfully renewed their contracts in this update of the catalog, used respectively for the treatment of adult patients with community-acquired pneumonia and acute bacterial skin and skin structure infections, as well as adult patients with advanced gastrointestinal stromal tumors who have previously received three or more kinase inhibitors.
Zai Lab's Chief Business Officer for Greater China, Zhu Tong, expressed that the company expects to launch A Keylok by the end of this year. The expected inclusion of A Keylok, along with the renewal of Nuzale and Qing Le, will further help domestic patients access treatment at more affordable costs. Josh Smiley, the company's President and Chief Operating Officer, mentioned that Zai Lab currently has six products included in the National Medical Insurance Catalogue and will continue to cooperate with the National Medical Security Administration to improve the affordability and accessibility of differentiated innovative therapies in China.
